Nucleophosmin (NPM1, B23) is a multifunctional phosphoprotein expressed in all tissues. The protein is mainly localized in nucleoli. In hematological malignancies, NPM1 belongs to commonly altered genes. Its mutation, always heterozygous, leads to the re-localization of the NPM1 protein from the nucleolus to the cytoplasm (NPM1c+). NPM1c+ is found in 30% of acute myeloid leukemia (AML). Our study showed that an AML patient, whose leukemia cells carried the NPM1c+ mutation and who was the recipient of allogeneic HSCT from a haploidentical donor, raised a robust allorestricted CD8+ T cell response directed against the NPM1wt protein. Favourably, the response against NPM1wt was not accompanied by side effects such as GvHD. Moreover, the induction of a high NPM1wt-specific response coincided with the decrease in NPM1c+ transcripts detected, implying a beneficial graft versus leukemia effect. On the basis of these results, we suppose that TCRs from allorestricted NPM1wt-specific T cells are worth studying in other recipients of grafts from haploidentical donors as a possible tool for TCR gene therapy.

Institute of Clinical and Experimental Hematology 1st Faculty of Medicine Charles University CZ 121 08 Prague Czech Republic

Institute of Haematology and Blood Transfusion CZ 128 20 Prague Czech Republic

Zobrazit více v PubMed

Falini B., Brunetti L., Sportoletti P., Martelli M.P. NPM1-mutated acute myeloid leukemia: From bench to bedside. Blood. 2020;136:1707–1721. doi: 10.1182/blood.2019004226. PubMed DOI

Chen S., He H., Wang Y., Liu L., Liu Y., You H., Dong Y., Lyu J. Poor prognosis of nucleophosmin overexpression in solid tumors: A meta-analysis. BMC Cancer. 2018;18:1–8. doi: 10.1186/s12885-018-4718-6. PubMed DOI PMC

Grisendi S., Mecucci C., Falini B., Pandolfi P.P. Nucleophosmin and cancer. Nat. Cancer. 2006;6:493–505. doi: 10.1038/nrc1885. PubMed DOI

Falini B., Mecucci C., Tiacci E., Alcalay M., Rosati R., Pasqualucci L., La Starza R., Diverio D., Colombo E., Santucci A., et al. Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype. N. Engl. J. Med. 2005;352:254–266. doi: 10.1056/NEJMoa041974. PubMed DOI

Papaemmanuil E., Gerstung M., Bullinger L., Gaidzik V.I., Paschka P., Roberts N.D., Potter N.E., Heuser M., Thol F., Bolli N., et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N. Engl. J. Med. 2016;374:2209–2221. doi: 10.1056/NEJMoa1516192. PubMed DOI PMC

Forghieri F., Riva G., Lagreca I., Barozzi P., Vallerini D., Morselli M., Paolini A., Bresciani P., Colaci E., Maccaferri M., et al. Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia. Oncotarget. 2019;10:869–882. doi: 10.18632/oncotarget.26617. PubMed DOI PMC

Greiner J., Ono Y., Hofmann S., Schmitt A., Mehring E., Götz M., Guillaume P., Döhner K., Mytilineos J., Döhner H., et al. Mutated regions of nucleophosmin 1 elicit both CD4+ and CD8+ T-cell responses in patients with acute myeloid leukemia. Blood. 2012;120:1282–1289. doi: 10.1182/blood-2011-11-394395. PubMed DOI

Wesierska-Gadek J., Penner E., Hitchman E., Kier P., Sauermann G. Nucleolar proteins B23 and C23 as target antigens in chronic graft-versus-host disease. Blood. 1992;79:1081–1086. doi: 10.1182/blood.V79.4.1081.bloodjournal7941081. PubMed DOI

Swoboda R.K., Somasundaram R., Caputo L., Berencsi K., Von Franzke P., Taylor D.D., Marincola F.M., Meropol N.J., Sigurdson E., Miller E., et al. Nucleophosmin is recognized by a cytotoxic T cell line derived from a rectal carcinoma patient. Int. J. Cancer. 2009;127:1124–1130. doi: 10.1002/ijc.25133. PubMed DOI PMC

Pearson H., Daouda T., Granados D.P., Durette C., Bonneil E., Courcelles M., Rodenbrock A., Laverdure J.-P., Côté C., Mader S., et al. MHC class I–associated peptides derive from selective regions of the human genome. J. Clin. Investig. 2016;126:4690–4701. doi: 10.1172/JCI88590. PubMed DOI PMC

Shraibman B., Barnea E., Kadosh D.M., Haimovich Y., Slobodin G., Rosner I., López-Larrea C., Hilf N., Kuttruff S., Song C., et al. Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. Mol. Cell. Proteom. 2019;18:1255–1268. doi: 10.1074/mcp.RA119.001524. PubMed DOI PMC

Narayan R., Olsson N., Wagar L.E., Medeiros B.C., Meyer E., Czerwinski D., Khodadoust M.S., Zhang L., Schultz L., Davis M.M., et al. Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin. PLoS ONE. 2019;14:e0219547. doi: 10.1371/journal.pone.0219547. PubMed DOI PMC

Amir A.L., Van Der Steen D.M., Van Loenen M.M., Hagedoorn R.S., De Boer R., Kester M.D., De Ru A.H., Lugthart G., van Kooten C., Hiemstra P., et al. PRAME-Specific Allo-HLA–Restricted T Cells with Potent Antitumor Reactivity Useful for Therapeutic T-Cell Receptor Gene Transfer. Clin. Cancer Res. 2011;17:5615–5625. doi: 10.1158/1078-0432.CCR-11-1066. PubMed DOI

Wilde S., Sommermeyer D., Frankenberger B., Schiemann M., Milosevic S., Spranger S., Pohla H., Uckert W., Busch D.H., Schendel D.J. Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity. Blood. 2009;114:2131–2139. doi: 10.1182/blood-2009-03-209387. PubMed DOI

Münz C., Obst R., Osen W., Stevanović S., Rammensee H.G. Alloreactivity as a source of high avidity peptide-specific human CTL. J. Immunol. 1999;162:25–34. PubMed

Sadovnikova E., Stauss H.J. Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: Reagents for tumor immunotherapy. Proc. Natl. Acad. Sci. USA. 1996;93:13114–13118. doi: 10.1073/pnas.93.23.13114. PubMed DOI PMC

Šťastná-Marková M., Hamšíková E., Hainz P., Hubáček P., Kroutilová M., Kryštofová J., Ludvíková V., Musil J., Pecherková P., Saláková M., et al. Pretransplant BK Virus-Specific T-Cell-Mediated Immunity and Serotype Specific Antibodies May Have Utility in Identifying Patients at Risk of BK Virus-Associated Haemorrhagic Cystitis after Allogeneic HSCT. Vaccines. 2021;9:1226. doi: 10.3390/vaccines9111226. PubMed DOI PMC

Rammensee H.-G., Bachmann J., Emmerich N.P.N., Bachor O.A., Stevanović S. SYFPEITHI: Database for MHC ligands and peptide motifs. Immunogenetics. 1999;50:213–219. doi: 10.1007/s002510050595. PubMed DOI

Stranzl T., Larsen M.V., Lundegaard C., Nielsen M. NetCTLpan: Pan-specific MHC class I pathway epitope predictions. Immunogenetics. 2010;62:357–368. doi: 10.1007/s00251-010-0441-4. PubMed DOI PMC

Ford M.L. Virally-induced heterologous immunity in renal transplant recipients: Important or inconsequential? Am. J. Transplant. 2016;16:1348–1349. doi: 10.1111/ajt.13657. PubMed DOI PMC

Heutinck K.M., La Yong S., Tonneijck L., Heuvel H.V.D., Van Der Weerd N.C., Van Der Pant K.A., Bemelman F.J., Claas F.H., Berge I.J.T. Virus-Specific CD8+T Cells Cross-Reactive to Donor-Alloantigen Are Transiently Present in the Circulation of Kidney Transplant Recipients Infected with CMV and/or EBV. Am. J. Transplant. 2016;16:1480–1491. doi: 10.1111/ajt.13618. PubMed DOI

Stranavova L., Pelak O., Svaton M., Hruba P., Fronkova E., Slavcev A., Osickova K., Maluskova J., Hubacek P., Fronek J., et al. Heterologous Cytomegalovirus and Allo-Reactivity by Shared T Cell Receptor Repertoire in Kidney Transplantation. Front. Immunol. 2019;10:2549. doi: 10.3389/fimmu.2019.02549. PubMed DOI PMC

Kuželová K., Brodská B., Fuchs O., Dobrovolná M., Soukup P., Cetkovský P. Altered HLA Class I Profile Associated with Type A/D Nucleophosmin Mutation Points to Possible Anti-Nucleophosmin Immune Response in Acute Myeloid Leukemia. PLoS ONE. 2015;10:e0127637. doi: 10.1371/journal.pone.0127637. PubMed DOI PMC

Martelli M.P., Gionfriddo I., Mezzasoma F., Milano F., Pierangeli S., Mulas F., Pacini R., Tabarrini A., Pettirossi V., Rossi R., et al. Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells. Blood. 2015;125:3455–3465. doi: 10.1182/blood-2014-11-611459. PubMed DOI

Du W., Xu A., Huang Y., Cao J., Zhu H., Yang B., Shao X., He Q., Ying M. The role of autophagy in targeted therapy for acute myeloid leukemia. Autophagy. 2020;17:2665–2679. doi: 10.1080/15548627.2020.1822628. PubMed DOI PMC

Carey A., Edwards D.K., Eide C.A., Newell L., Traer E., Medeiros B.C., Pollyea D.A., Deininger M.W., Collins R.H., Tyner J.W., et al. Identification of interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia. Cell Rep. 2017;18:3204–3218. doi: 10.1016/j.celrep.2017.03.018. PubMed DOI PMC

Absence of pre-transplant T cell response against LAA is associated with Flt3-ITD mutation and increased relapse-risk in AML patients with HSCT